By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

It was led by venture capital firm ARCH Venture Partners, with other prominent biotech investors participating, including OrbiMed, Fairmount, Fidelity Management, and Sanofi Ventures. Mirador ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Almost five years after leaving Spark Therapeutics, Dr. Katherine High is back at the helm of a gene therapy company with ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...